A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma

NCT07583771 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

186

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Adenocarcinoma
Non Small Cell Lung Cancer
Advanced Solid Tumors
Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)

Interventions

DRUG: CS08399

Sponsor

Chipscreen Biosciences, Ltd.